Samlyn Capital, Llc - Significant Ownership

Signature - Title
By: Samlyn, LP, its sole member, By: Samlyn GP, LLC, its general partner, By: /s/ Robert Pohly* - Robert Pohly, Managing Member
Location
New York, NY
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Samlyn Capital, Llc.

Significant Ownership of Samlyn Capital, Llc

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
PCT PureCycle Technologies, Inc. Common Stock, par value $0.001 per share 8.8% $244M $73.6M 16.7M +43.1% SAMLYN CAPITAL, LLC Jun 30, 2025
VINP Vinci Partners Investments Ltd. Class A Common Shares, par value US$0.00005 per share 4.8% $24.1M -$36.1K 2.36M -0.15% SAMLYN CAPITAL, LLC Mar 31, 2025
INZY Inozyme Pharma, Inc. Common Stock, par value $0.0001 per share 0% $0 0 Samlyn Capital, LLC Dec 31, 2024
CRVS Corvus Pharmaceuticals, Inc. Common Stock, par value $0.0001 per share 0% $0 -$22M 0 -100% SAMLYN CAPITAL, LLC Jun 30, 2025
NKTR Nektar Therapeutics Common Stock, $0.0001 par value 0% $0 -$4.74M 0 -100% SAMLYN CAPITAL, LLC Mar 31, 2025

Schedules 13D/G Reported by Samlyn Capital, Llc:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Date Filed
* An asterisk sign (*) next to the price indicates that the price is likely invalid.